BrainAurora Medical Technology Limited (BRAINAURORA-B) announced that all resolutions proposed at its 18 June 2026 online annual general meeting were approved by poll, each securing approximately 99.97% of votes cast.\n\nKey outcomes\n• Adoption of FY 2025 Results: Shareholders endorsed the audited consolidated financial statements and the Directors’ and auditor’s reports for the year ended 31 December 2025, with 241.67 million votes in favour versus 70,000 against.\n\n• Board Composition Unchanged: Five directors—non-executives Mr. Deng Feng, Mr. Yang Fan and Ms. Wang Jingbo, and independent non-executives Dr. Duan Tao and Mr. Tu Lei—were all re-elected with 99.97% approval.\n\n• Remuneration and Auditor: The Board was authorised to fix directors’ remuneration, and Deloitte Touche Tohmatsu was re-appointed as auditor; both motions received 99.97% support.\n\n• Capital Management Mandates: Shareholders renewed three key mandates:\n – General issuance mandate allowing the Board to allot and issue up to 20% of issued shares (approx. 271.66 million shares).\n – Share repurchase mandate of up to 10% of issued shares (approx. 135.83 million shares).\n – Extension of the issuance mandate by the amount of shares repurchased.\n\nParticipation and voting structure\n• Shares in issue as at the meeting date: 1.36 billion.\n• Shares voted: 241.74 million, representing a turnout of about 17.80%.\n• HoldCo, which holds 85.17 million unvested shares under the Pre-IPO Share Award Scheme, abstained from voting as required by Hong Kong Listing Rules.\n\nAdministrative details\nTricor Investor Services Limited acted as scrutineer. All directors except Dr. Duan Tao attended the AGM electronically, and no shareholders indicated intentions to vote against or abstain on any resolution in advance.\n\nThe strong approval rates reaffirm investor confidence in BrainAurora Medical’s leadership and strategic flexibility as the company progresses into the 2026 financial year.